SK121896A3 - Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction - Google Patents

Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction Download PDF

Info

Publication number
SK121896A3
SK121896A3 SK1218-96A SK121896A SK121896A3 SK 121896 A3 SK121896 A3 SK 121896A3 SK 121896 A SK121896 A SK 121896A SK 121896 A3 SK121896 A3 SK 121896A3
Authority
SK
Slovakia
Prior art keywords
endothelial
compounds
nitric oxide
releasing
dab
Prior art date
Application number
SK1218-96A
Other languages
English (en)
Slovak (sk)
Inventor
Eike A Noack
Georg Kojda
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of SK121896A3 publication Critical patent/SK121896A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
SK1218-96A 1994-03-30 1995-03-28 Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction SK121896A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4410997A DE4410997A1 (de) 1994-03-30 1994-03-30 Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
PCT/DE1995/000421 WO1995026725A1 (de) 1994-03-30 1995-03-28 Pharmazeutische zubereitingen und arzneistoffe zur prävention und behandlung endothelialer dysfunktion

Publications (1)

Publication Number Publication Date
SK121896A3 true SK121896A3 (en) 1998-10-07

Family

ID=6514213

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1218-96A SK121896A3 (en) 1994-03-30 1995-03-28 Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction

Country Status (19)

Country Link
EP (1) EP0752858A1 (lt)
JP (1) JPH09510979A (lt)
CN (1) CN1150387A (lt)
BG (1) BG63073B1 (lt)
CA (1) CA2186783A1 (lt)
CZ (1) CZ283696A3 (lt)
DE (2) DE4410997A1 (lt)
EE (1) EE9600139A (lt)
FI (1) FI963883A0 (lt)
HU (1) HU220165B (lt)
IS (1) IS4365A (lt)
LT (1) LT4310B (lt)
LV (1) LV11666B (lt)
MX (1) MX9604434A (lt)
NO (1) NO964102D0 (lt)
PL (1) PL316528A1 (lt)
SI (1) SI9520047A (lt)
SK (1) SK121896A3 (lt)
WO (1) WO1995026725A1 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
DE19604361C2 (de) * 1996-02-07 1999-01-14 Sanol Arznei Schwarz Gmbh Verwendung gasdichter Primärpackmittel für pharmazeutische Zusammensetzungen
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
DE19726812A1 (de) * 1997-06-25 1999-01-07 Isis Pharma Gmbh Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
DE19745622A1 (de) * 1997-10-16 1999-04-22 Isis Pharma Gmbh Neue Salpetersäureester des Pentaerythrits
JP5187991B2 (ja) * 1997-10-17 2013-04-24 アーク・セラピューティックス・リミテッド レニン−アンジオテンシン系の阻害剤の使用
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU5503199A (en) * 1998-06-24 2000-01-10 Alpharma-Isis Gmbh And Co. Kg Analytic substrates and antioxidative agents
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
AU780261B2 (en) 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US9365574B2 (en) * 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
RU2467748C1 (ru) * 2011-08-08 2012-11-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
JP5360939B2 (ja) * 2011-09-28 2013-12-04 国立大学法人徳島大学 ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR984523A (fr) * 1949-02-10 1951-07-06 Phosphate de trinitro-triéthanolamine et procédé de préparation
DE1695897C3 (de) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-Acyl-sydnonimine, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US3886186A (en) * 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
GB1356374A (en) * 1971-04-29 1974-06-12 American Home Prod Mononitrate esters of 1,3 3,6-dianhydro-d-glucitol
DE2532124C3 (de) * 1975-07-18 1979-04-19 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von 4-Amino-morpholin
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE2623800C3 (de) * 1976-05-28 1978-11-23 Sanol Schwarz-Monheim Gmbh, 4000 Duesseldorf Obersättigte wässerige Isosorbiddinitrat-Lösung, Herstellungsverfahren und Verwendung
US4065488A (en) * 1977-02-24 1977-12-27 American Home Products Corporation Process for preparing 1,4:3,6-dianhydro-D-glucitol 2-nitrate
DE2903927C2 (de) * 1979-02-02 1981-03-12 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Verfahren zur selektiven Herstellung von Isosorbid-5-nitrat
DE3028873C2 (de) * 1980-07-30 1983-10-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von 1,4 zu 3,6-Dianhydro-D-glucit-5-nitrat (Isosorbid-5-nitrat)
DE3102947A1 (de) * 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
FR2500835A1 (fr) * 1981-02-27 1982-09-03 Poudres & Explosifs Ste Nale Procede de synthese des mononitrates d'isosorbide
DE3117612A1 (de) * 1981-05-05 1982-11-25 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von isosorbid-5-nitrat
DE3124410A1 (de) * 1981-06-22 1983-01-05 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-2-nitrat
JPS5910513A (ja) * 1982-07-12 1984-01-20 Nitto Electric Ind Co Ltd 医薬製剤
DE3325652A1 (de) * 1983-07-15 1985-01-24 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Feste, stabile isosorbid-5-mononitrat enthaltende arzneimittelzubereitungen und verfahren zu ihrer herstellung
DE3328094A1 (de) * 1983-08-04 1985-02-21 H. Trommsdorff GmbH & Co, 5110 Alsdorf Phlegmatisierte pharmazeutische zubereitung von explosionsfaehigen salpetersaeureestern
DE3479800D1 (en) * 1983-11-25 1989-10-26 Toshin Chemical Co A method for the preparation of isosorbide-5-nitrate and sodium isosorbide-5-nitrate hydrate as a precursor thereof
DD244980A1 (de) * 1985-12-18 1987-04-22 Isis Chemie Zwickau Veb Verfahren zur herstellung von n-morpholinoaminoacetonitril und dessen hydrochlorid
DD293492A5 (de) * 1987-11-26 1991-09-05 Isis-Chemie Gmbh,De Verfahren zur herstellung einer glyceroltrinitrat-arzneiform mit gleichmaessig verzoegerter arzneistofffreisetzung
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
DE4007705C1 (lt) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia

Also Published As

Publication number Publication date
IS4365A (is) 1996-09-25
LT4310B (lt) 1998-03-25
LV11666A (lv) 1997-02-20
CA2186783A1 (en) 1995-10-12
NO964102L (no) 1996-09-27
JPH09510979A (ja) 1997-11-04
LV11666B (en) 1997-06-20
PL316528A1 (en) 1997-01-20
HU220165B (hu) 2001-11-28
HU9602671D0 (en) 1996-11-28
AU698359B2 (en) 1998-10-29
AU2134595A (en) 1995-10-23
FI963883A (fi) 1996-09-27
HUT76676A (en) 1997-10-28
DE4410997A1 (de) 1995-10-26
CN1150387A (zh) 1997-05-21
BG63073B1 (bg) 2001-03-30
LT96148A (en) 1997-12-29
DE19580261D2 (de) 1997-05-28
BG100930A (en) 1997-07-31
MX9604434A (es) 1997-12-31
EE9600139A (et) 1997-04-15
FI963883A0 (fi) 1996-09-27
CZ283696A3 (cs) 1998-03-18
NO964102D0 (no) 1996-09-27
EP0752858A1 (de) 1997-01-15
WO1995026725A1 (de) 1995-10-12
SI9520047A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
SK121896A3 (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
US5973011A (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
US7244749B2 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
EP0930076B1 (en) Pharmaceutical compositions comprising CS-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
EP1303304A2 (en) Pharmaceutical combinations for treatment and prevention of diabetes mellitus
AU2002211452A1 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
CZ20012343A3 (cs) Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny nikotinové pro kardiovaskulární indikace
AU2003258909A1 (en) Dosage forms and related therapies
WO1994016740A1 (en) The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
US20220265776A1 (en) Combination
CA2355645A1 (en) Increasing brain glucose utilization
JPH0296537A (ja) プロタミンの使用における有害作用の予防または減少用組成物
CA2501717C (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
Bennett et al. Coronary sinus diverticulum containing posteroseptal accessory pathway
Morris et al. Small molecule approaches to the prevention of restenosis
JP2008094852A (ja) 医薬
JPS63201125A (ja) 胃十二指腸潰瘍の治療に対する相乗的抗分泌作用を有する薬剤組成物
NZ539695A (en) Dosage forms and related therapies